Introduction: Donepezil enhances the function of cholinergic nerves by increasing the concentration of acetylcholine, thereby improving clinical symptoms in patients with Alzheimer's disease (AD). However, the neural mechanisms of how donepezil modulates the effective connectivity (EC) network of cholinergic system in AD patients remain unknown. We speculated that the effective network of the cholinergic system changes in AD patients after donepezil intervention.
Methods: We employed resting-state functional magnetic resonance imaging and Granger causality analysis approach to explore changes in the effective connectivity network of the basal forebrain in AD patients before and after donepezil intervention. This study included 32 participants, including 16 healthy controls (HCs) and 16 AD patients. In a 3T MRI scanner, the 16 AD patients were scanned before and after the donepezil intervention. To compare EC differences between the three groups of participants, ANOVA and -tests analysis were employed.
Results: Compared to baseline status, AD patients after donepezil intervention had an increased EC from left middle occipital gyrus to right medial septum/diagonal bands. Compared to HCs, AD patients after donepezil intervention had an increased EC from right inferior frontal gyrus/orbit part to right medial septum/diagonal bands, AD patients before donepezil intervention had a reduced EC from right precuneus to right medial septum/diagonal bands. A significant positive correlation was found between EC values in right precuneus and Mini-Mental State Examination in pre-intervention AD patients ( = 0.7338, = 0.0012).
Discussion: Our study showed that effective connectivity of brain regions associated with the default mode network in the cholinergic pathway was enhanced after donepezil intervention. The results of this study will help us to better understand the neural mechanisms of donepezil intervention in AD and to find clinical targets for intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039922 | PMC |
| http://dx.doi.org/10.3389/fnagi.2024.1362790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rg1 Improves Alzheimer's disease by Regulating Mitochondrial Dynamics Mediated by the AMPK/Drp1 Signaling Pathway.
J Ethnopharmacol
December 2024
Hubei University of Chinese Medicine, Basic Medical College, Wuhan, Hubei, 430070, China; Engineering Research Center of TCM Protection Technology and New Product Development for the Elderly Brain Health, Ministry of Education, Wuhan, Hubei, 430070, China; Hubei Shizhen Laboratory, Wuhan, Hubei, 430070, China. Electronic address:
Ethnopharmacological Relevance: Alzheimer's disease (AD) is the most prevalent form of dementia, characterized by a complex pathogenesis that includes Aβ deposition, abnormal phosphorylation of tau protein, chronic neuroinflammation, and mitochondrial dysfunction. In traditional medicine, ginseng is revered as the 'king of herbs'. Ginseng has the effects of greatly tonifying vital energy, strengthening the spleen and benefiting the lungs, generating fluids and nourishing the blood, and calming the mind while enhancing intelligence.
View Article and Find Full Text PDFPatterns, determinants, and outcomes of early use of antidementia drugs: A 6-year multicenter cohort study in Thailand.
Arch Gerontol Geriatr
December 2024
Unit of Excellence on Research in Health Outcomes and Patient Safety in Elderly, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand; Division of Social and Administrative Pharmacy (SAP), Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand. Electronic address:
Background: Evidence on antidementia drugs (ADD) use in developing countries, where accessibility to ADD is challenging, is limited. Our aim was to examine prescribing patterns, factors, and outcomes associated with the early-ADD use (within 3 months from diagnosis) in people with dementia.
Methods: A retrospective cohort study included individuals aged ≥ 60 years with dementia from three hospitals in Thailand between 2015 and 2020.
Efficacy of Donepezil for Fatigue and Psychological Symptoms in Post-COVID-19 Condition: Study Protocol for a Multicenter Randomized, Placebo-controlled, Double-blind Trial.
Ann Clin Epidemiol
October 2024
Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Background: Approximately 30% of coronavirus disease 2019 COVID-19 patients develop fatigue and psychological symptoms. We previously demonstrated the efficacy of donepezil, an acetylcholinesterase inhibitor that is widely used to treat dementia, in basic research.
Methods: This is a multicenter, double-blind, randomized, controlled, phase II clinical trial in which 120 patients with COVID-19 will be randomized in a 1:1 ratio to a donepezil or placebo group.
Current Updates on Nanotechnology-based Drug Delivery Platforms for Treating Alzheimer's with Herbal Drugs.
Pharm Nanotechnol
December 2024
Institute for Medical Research, University of Sharjah, Sharjah United Arab Emirates.
Alzheimer's disease (AD) is an irreversible brain disorder that led to memory loss and disrupts daily life. Earlier strategies to treat AD such as acetylcholinesterase inhibitor (AChEI) drugs are not showing effectiveness due to the inability to cross the blood-brain barrier. Moreover, traditional AChEI provides limited efficacy in terms of bioavailability and solubility for treating AD treatment.
View Article and Find Full Text PDFAnti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics.
Adv Clin Exp Med
December 2024
NeuroActiva, Inc., San Jose, USA.
The so-called "amyloid cascade hypothesis" provides an elegant explanation of Alzheimer's disease (AD), has motivated the amyloid-lowering therapeutic strategy, and led to the elaboration of a rich experimental and conceptual toolkit for the field to progress. But it might be incorrect. The scientific evidence base supporting the efficacy and safety of current anti-amyloid antibody treatments in AD is weak.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!